AUTOLOGOUS TRANSPLANT IN LYMPHOMAS IN CURRENT ERA OF IMMUNOTHERAPY
Abstract
-References
Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non- hodgkin’s lymphoma. N Engl J Med 1995;333:1540-5.
Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate- grade or high-grade non-Hodgkin’s lymphoma. N Engl J Med 1987;316:1493-8.
Pervez S. Non-hodgkin lymphoma (NHL) in Pakistan. Int J Mol Cell Med 2012;1:62-3.
Ali N, Adil SN, Shaikh MU. Autologous hematopoietic stem cell transplantation-10 years of data from a developing country. Stem Cells Transl Med 2015;4:873-7.
Philip T, Hartmann O, Biron P, et al. High-dose therapy and autologous bone marrow transplantation in partial remission after first-line induction therapy for diffuse non-Hodgkin’s lymphoma. J Clin Oncol 1988;6:1118-24.
Santini G, Congiu AM, Coser P, et al. Autologous bone marrow transplantation in 100 cases of poor- prognosis non-Hodgkin’s lymphoma. A report of the Non-Hodgkin’s lymphoma cooperative study group. In: Dicke KA, Keating A, editors. Autologous Bone Marrow Transplantation. Arlington (Texas): Proceeding of the Sixth International Symposium; 1993. p. 75-82.
Hamadani M, Hari PN, Zhang Y, et al. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2014;20:1729-36.
Gisselbrecht C, Schmitz N, Mounier N, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: Final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol 2012;30:4462-9.
Zhang W, Jiao L, Zhou DB, et al. Rituximab purging and maintenance therapy combined with autologous stem cell transplantation in patients with diffuse large B-cell lymphoma. Oncol Lett 2010;1:733-8.
Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol Blood Marrow Transplant 2006;12:1065-72.
Josting A, Müller H, Borchmann P, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin’s lymphoma. J Clin Oncol 2010;28:5074-80.
Bartlett NL, Younes A, Carabasi MH, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2008;111:1848 54.
Forero-Torres A, Leonard JP, Younes A, et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009;146:171-9.
Rothe A, Sasse S, Goergen H, et al. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: The German Hodgkin study group experience. Blood 2012;120:1470-2.
Sasse S, Rothe A, Goergen H, et al. Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma. Leuk Lymphoma 2013;54:2144-8.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors retain copyright and grant the Journal of Cancer & Allied Specialties (JCAS) right-of-first publication. In addition, the work will be simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license. This license allows others to share the work in whole or part (for non-commercial purpose), with an acknowledgement of the work’s authorship and initial publication in JCAS.
Furthermore, authors are free to enter into separate contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to share their work online or in medical or scientific conferences prior to or during submission process.
